KALV
KalVista Pharmaceuticals, Inc. (KALV) PESTLE Analysis Analysis (2026)
Overall Score
Political
No major political or regulatory developments were reported this month.
Economic
KALV remains unprofitable with negative TTM margins and cash flow, but it still has a strong current ratio of 5.58 and cash per share of 5.94.
Valuation remains elevated at 12.9x EV/Sales despite negative earnings and free cash flow, keeping the economic profile mixed.
Social
No new social or demand-related developments were reported this month.
Technological
No new product, pipeline, or R&D milestone news was reported this month.
Legal
No new litigation or legal developments were reported this month.
Environmental
No new environmental or sustainability developments were reported this month.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on KalVista Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.